PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer

INTRODUCTION: Endeavors in the molecular characterization of breast cancer opened the doors to endocrine therapies in ER+/HER2- breast cancer, increasing response rates substantially. Despite that, taxane-based neoadjuvant chemotherapy is still a cornerstone for achieving breast-conserving surgery a...

Descripción completa

Detalles Bibliográficos
Autor principal: Ozcan, Gulnihal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493393/
https://www.ncbi.nlm.nih.gov/pubmed/37700842
http://dx.doi.org/10.3389/fonc.2023.1216438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493393/
https://www.ncbi.nlm.nih.gov/pubmed/37700842
http://dx.doi.org/10.3389/fonc.2023.1216438

Ejemplares similares